| ID Source | ID |
|---|---|
| PubMed CID | 9180 |
| CHEBI ID | 82397 |
| SCHEMBL ID | 297515 |
| MeSH ID | M0102335 |
| Synonym |
|---|
| benzo(a)acridine |
| benz[a]acridine |
| einecs 205-929-7 |
| 7-azabenz(a)anthracene |
| benz(a)acridine |
| 1,2-benzacridine |
| ccris 2466 |
| brn 0009262 |
| benzo[a]acridine |
| d4q8mr98lu , |
| unii-d4q8mr98lu |
| 225-11-6 |
| C19337 |
| AKOS024319582 |
| 12041-95-1 |
| benzacridine |
| FT-0631878 |
| 85495-86-9 |
| SCHEMBL297515 |
| benz(a)acridine [iarc] |
| CHEBI:82397 |
| JEGZRTMZYUDVBF-UHFFFAOYSA-N |
| DTXSID9075371 |
| benz[a]acridine, bcr(r) certified reference material |
| debenzolyation |
| Q27155920 |
| 1,2-benzacridin |
| benz (a) acridine (purity) |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-response relationships were obtained for DBa,hAC as well as for BaP." | ( Experimental studies on the carcinogenicity of five nitrogen containing polycyclic aromatic compounds directly injected into rat lungs. Brune, H; Deutsch-Wenzel, RP; Grimmer, G, 1983) | 0.27 |
| Class | Description |
|---|---|
| organonitrogen heterocyclic compound | Any organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms. |
| polycyclic heteroarene | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||